← All indications
Essential Hypertension
Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500
Subtype terms (1)
More specific conditions that are subtypes of Essential Hypertension in the MeSH hierarchy.
Drugs by status
Phase 4 trials (40)
- simvastatin
- azilsartan
- fimasartan
- candesartan
- canrenone
- chlorthalidone
- atenolol
- nifedipine
- enalapril
- amlodipine
- lacidipine
- levamlodipine
- manidipine
- nebivolol
- olmesartan
- atorvastatin
- valsartan
- salvianolate
- acetylsalicylic acid
- aliskiren
- thiamine
- xuezhikang
- lercanidipine
- ramipril
- losartan
- eplerenone
- doxazosin
- metoprolol
- hydrochlorothiazide
- sacubitril
- +10 more
Phase 3 trials (35)
- ezetimibe
- agsct101
- allisartan isoproxil
- darbepoetin alfa
- captopril
- cetirizine
- esaxerenone
- bexagliflozin
- ethanol
- rosuvastatin
- imidapril
- indapamide
- irbesartan
- furosemide
- carvedilol
- dexmedetomidine
- sph3127
- midazolam
- hibiscus sabdariffa
- dapagliflozin
- aducanumab
- sodium chloride
- omeprazole
- arginine
- br101801
- aju-c52l
- atb-1013
- ad-209
- ad-223a
- Deunoxavir
- +5 more
Phase 2 trials (12)
Phase 1 trials (16)
Organizations
Organization Involved with Phase 4 Indications (50)
- Daiichi Sankyo
- Sankyo
- Eisai
- Takeda
- Sumitomo
- Servier
- AstraZeneca
- Merck
- Merck Serono
- Merck KGaA
- Novartis
- Bayer
- Dong-A Pharmaceutical
- GlaxoSmithKline
- Hanlim Pharm. Co., Ltd.
- Simcere Pharmaceutical Co., Ltd
- Shenzhen Ausa Pharmed Co.,Ltd
- Boehringer Ingelheim
- Pacific Pharmaceuticals
- Shanghai Shyndec Pharmaceutical Co.,Ltd.
- TSH Biopharm Corporation Limited
- ZonMw: The Netherlands Organisation for Health Research and Development
- Aarhus University
- Anhui Medical University
- Radboud University
- Seoul National University
- St. John's Research Institute
- Sichuan University
- University of Manchester
- University of Pavia
- +20 more
Organization Involved with Phase 3 Indications (73)
- Abbott
- Pfizer
- HanAll BioPharma Co., Ltd.
- Hengrui Therapeutics, Inc.
- Menarini Group
- Sponsor GmbH
- Symplmed Pharmaceuticals LLC
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Chong Kun Dang Pharmaceutical
- IlDong Pharmaceutical Co Ltd
- Stendhal Americas, S.A.
- Theracos
- Huazhong University of Science and Technology
- Ajou University
- Harvard University
- Dong-A University
- Federal University of Health Science of Porto Alegre
- Federal University of Rio Grande do Sul
- Gachon University
- Hanyang University
- Harbin Medical University
- Inje University
- Jeju National University
- Korea University
- Kosin University
- Kyung Hee University
- Ilsan Hospital
- Seoul Veterans Hospital
- Yonsei University
- Xuzhou Medical University
- +43 more
Organization Involved with Phase 2 Indications (50)
- Ablative Solutions, Inc.
- Actelion
- Recordati
- Eli Lilly
- Handok Pharmaceuticals Co., Ltd.
- Jeil Pharmaceutical Co., Ltd.
- Leadiant Biosciences, Inc.
- LG
- Parexel
- RMJ Holdings, LLC
- Cytos Biotechnology AG
- Quantum Genomics SA
- RostaQuo S.p.A.
- Shanghai Pharmaceuticals Holding Co., Ltd
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Maastricht University
- Baylor University
- Katholieke Universiteit Leuven
- Masaryk University
- Medical University of Gdansk
- Osaka University
- Russian Academy of Medical Sciences
- The Korean Society of Ginseng
- University of Lausanne
- University of Valencia
- Orange County Research Center
- Government of Russia
- Isfahan University
- University of Ljubljana
- +20 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (12)
- Roxane Laboratories
- University of London
- Fr Muller Homoeopathic Medical College
- Johns Hopkins University
- University of Bern
- Creighton University
- University of Copenhagen
- University of Texas at Houston
- Aristotle University of Thessaloniki
- Rajiv Gandhi University of Health Sciences
- Rouen Normandy University
- Nepal Development Society